Trials / Terminated
TerminatedNCT05068856
A Study of HRS2543 in Patients With Advanced Tumors
A Phase I, Multi-Center, Open Label, Dose Escalation/Expansion Study of HRS2543 in Patients With Advanced Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability of HRS2543 in patients with advanced tumors and to determine the recommended phase II dose (RP2D) of HRS2543
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS2543 | Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set. Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC. |
Timeline
- Start date
- 2021-12-28
- Primary completion
- 2024-05-15
- Completion
- 2024-05-15
- First posted
- 2021-10-06
- Last updated
- 2024-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05068856. Inclusion in this directory is not an endorsement.